- San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma
- State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full Capacity
- The Center is Structured to Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D; Anticipated to be One of the Largest Centers for Specialty Plasma Collection in the U.S.
REHOVOT, Israel and HOBOKEN, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma's collection center in San Antonio, TX. The approval was obtained following an on-site inspection made by the FDA during February 2026.
The center is now cleared to commence commercial sales of normal source plasma. The 11,100 square foot San Antonio facility supports up to 50 donor beds, with a planned capacity of approximately 50,000 liters per year at its full capacity, and is anticipated to be one of the largest collection centers for specialty plasma in the U.S.